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The weekly ILI morbidity and inﬂuenza positive samples
in selected sites
Conclusion: This active surveillance showed a certain
existence of ILI morbidity and hospitalization especially
among 0-4 age children, but there was no death observed
during this period. In addition there were some cases of ILI
seen while no inﬂuenza was detected. A multiple year study
is necessary to ﬁgure out the disease burden of inﬂuenza and
at the same time further study including etiological study
is also necessary. At the moment, this community based
information is useful to respond current pandemic (H1N1)
2009.
doi:10.1016/j.ijid.2010.02.1676
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Background: Pandemic Inﬂuenza Virus (AH1N1) has been
identiﬁed as the cause of respiratory infection worldwide,
has been linked to severe respiratory failure requiring fre-
quently ICU admissions
Methods: We describe the clinical and epidemiologic
characteristics of 100 patients(p) hospitalized at these
intensive care units with laboratory conﬁrmed (RT-PCR) or
acute febrile respiratory illness epidemiologically linked.
Results: 60p were conﬁrmed and 40 were epidemiogically
suspected cases. Mean Age: 45 yrs (± 16,8); 84%< 60yrs
Clinical proﬁle: cough (96%), dyspnea (93%), fever(90%),
bronchospasm (51%), headache (41%), myalgias(42%),
obtundness (35%)
Risk Factors: 31p had a body mass index >30; in 13% obe-
sity was the only risk factor. COPD (33%), cardiovascular
disease(19%), diabetes(16%), asthma(14%), pregnancy(10%).
White count cell in 70p was less than 10.000. 76p had less
than 1000 lynphocites, CPK wes elevated in 60p All tested
patients had elevated LDH; in 37/80 p>1000 IU, Most p (82)
showed bilateral interstitial alveolar images.
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iAcute Respiratoty Distress Sindrome was present in 60 p.
nvasive Mechanical Ventilation was instituted in 54 p. Alve-
lar recruitment maneuvers were necessary in 36 p; in 20
f which oxemia improved. When recruitment failed prone
osition was instituted: 7/12p also improved St pneumo-
iae was identiﬁed in 22 p (18 in tracheal aspirates and 4 in
lood cultures). In 84 p Oseltamivir was indicated; average
ose 150mg per day for 7 days. Pts who did not respond to
reatment or in obese the dose was increased to 450mg. Cor-
icosteroid were indicated most due to bronchospasm(61p)
he most important complications were trombosis (7p) and
eptic shock (35p).The most common cause of death (24/28)
as respiratory failure
Conclusion: The vast majority of our patients were
ounger than 60. High frequency of bronchospasm, myal-
ia and obtundness. Obesity and pregnancy, are special risk
actors. Lymphopenia, elevated LDH and CPK represent lab-
ratory ﬁndings. Both lungs are usually compromised.
These patients have high mortality linked to respiratory
efractory failure.
oi:10.1016/j.ijid.2010.02.1677
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Background: The ongoing pandemic of 2009/H1N1
nﬂuenza has increased the awareness of the impact and
npredictable nature of inﬂuenza. This in turn has raised
he interest in the development of additional drugs to treat
he disease when vaccinations fall short. The patient pop-
lation of most concern are those classiﬁed as ‘‘high-risk’’
here inﬂuenza causes substantial morbidity and mortality.
his high-risk group comprises individuals with underly-
ng chronic disease. In this study, efﬁcacy and safety of
ntravenous administration of peramivir were evaluated in
